TWM624636U - Structure of micro-complex with ingredients and yeast - Google Patents
Structure of micro-complex with ingredients and yeast Download PDFInfo
- Publication number
- TWM624636U TWM624636U TW110209436U TW110209436U TWM624636U TW M624636 U TWM624636 U TW M624636U TW 110209436 U TW110209436 U TW 110209436U TW 110209436 U TW110209436 U TW 110209436U TW M624636 U TWM624636 U TW M624636U
- Authority
- TW
- Taiwan
- Prior art keywords
- yeast
- active ingredient
- core body
- particulate structure
- structure containing
- Prior art date
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本創作係關於一種含活性成分酵母之微粒結構,尤指至少包含核心體及包覆體的雙層複合微粒結構,用以保護有效成分不受胃酸破壞,調整寵物自體發炎。 This creation is about a particle structure containing active ingredient yeast, especially a double-layer composite particle structure including at least a core body and a covering body, which is used to protect the active ingredient from being damaged by gastric acid and adjust the pet's auto-inflammation.
傳統上寵物的營養品以錠劑或是粉狀為主,這樣的形態在未經特殊處理的狀況下容易受到溫度、濕度、甚至細菌汙染的狀態;而在服用之後,未經處理的營養品容易被胃酸及酵素分解。因此,改善有效成分的包覆,提高儲存穩定性及有效性是最重要的課題之一。 Traditionally, pet nutrition products are mainly in the form of lozenges or powders, which are susceptible to temperature, humidity, and even bacterial contamination without special treatment; and after consumption, untreated nutrition products Easily broken down by stomach acid and enzymes. Therefore, it is one of the most important issues to improve the coating of active ingredients and improve storage stability and effectiveness.
目前寵物異位性皮膚炎與自體炎症疾病多以抗組織胺及類固醇控制,抗組織胺經過臨床統計,僅對約三成的動物有效;而類固醇是現在使用最普遍的應對方式,但是長期使用類固醇可能造成永久且嚴重的後遺症。因此越來越多人使用酵素與益生菌的調養方式,取代繁重的藥物控制,但益生菌與酵素皆容易被胃酸破壞,保存也是另一個重大的問題,不穩定的品質可能造成對生物體更大的危害。 At present, pet atopic dermatitis and auto-inflammatory diseases are mostly controlled by antihistamines and steroids. After clinical statistics, antihistamines are only effective for about 30% of animals; steroids are the most commonly used coping methods, but long-term use Steroids can cause permanent and serious sequelae. Therefore, more and more people use enzymes and probiotics to replace the heavy drug control, but both probiotics and enzymes are easily destroyed by gastric acid, and preservation is also another major problem. big hazard.
有鑑於此,本新型創作之目的,即在提供一種保護酵母與活性成分不受胃酸破壞,並且可以提高保存穩定性的微粒結構,包含核心體與包覆體,核心體為微粒正中心的空間,是微粒最主要搭載成分的部分, 應包含活性成分與酵母,具有調整體質、保護腸道健康,可調整體內發炎反應,核心體應完全包覆於包覆體內,以防止洩漏。包覆體應包覆於核心體外圍,具有隔絕核心體與外圍環境之效果,包覆體可於體內輸送中保護活性成分,並且提高儲存穩定性。 In view of this, the purpose of this novel creation is to provide a particle structure that protects yeast and active ingredients from gastric acid damage and can improve storage stability, comprising a core body and a coating body, and the core body is the space in the center of the particle. , is the most important part of the particles carried by the particles, It should contain active ingredients and yeast, which can adjust the constitution, protect intestinal health, and adjust the inflammatory response in the body. The core body should be completely wrapped in the coating body to prevent leakage. The covering body should cover the periphery of the core body, and has the effect of isolating the core body and the surrounding environment. The covering body can protect the active ingredient during in vivo delivery and improve the storage stability.
根據前述之含活性成分酵母之微粒結構,其中活性成分來源包括動物、植物、微生物等。 According to the above-mentioned active ingredient-containing yeast particle structure, the source of the active ingredient includes animals, plants, microorganisms and the like.
根據前述之含活性成分酵母之微粒結構,其中酵母為啤酒酵母或其衍生物。 According to the aforementioned microparticle structure containing yeast as an active ingredient, the yeast is Saccharomyces cerevisiae or a derivative thereof.
根據前述之含活性成分酵母之微粒結構,其中包覆體包括多醣衍生物,如葡聚醣、澱粉、纖維素、環糊精等 According to the aforementioned microparticle structure of yeast containing active ingredient, the coating includes polysaccharide derivatives such as dextran, starch, cellulose, cyclodextrin, etc.
根據前述之含活性成分酵母之微粒結構,其中微粒結構包含防潮劑、抗氧化劑、吸濕劑、螯合劑、膨潤劑、黏合劑等 According to the aforementioned particulate structure of yeast containing active ingredient, wherein the particulate structure comprises moisture-proofing agent, antioxidant, hygroscopic agent, chelating agent, swelling agent, adhesive, etc.
根據前述之含活性成分酵母之微粒結構,其可作為粉劑、膠囊、粉包或是錠劑等。 According to the aforementioned microparticle structure of the yeast containing the active ingredient, it can be used as powder, capsule, powder packet or lozenge.
11:包覆體 11: Covering body
12:核心體 12: Core Body
21:活性成分 21: Active Ingredients
22:酵母 22: Yeast
23:益生元 23: Prebiotics
〔圖1〕含活性成分酵母之微粒結構剖面圖 [Fig. 1] A cross-sectional view of the microparticle structure containing the active ingredient yeast
以下針對本創作的實施提供例提供說明性之描述,但這並非本創作實施之唯一形式,創作中含實施例之方法步驟及合成順序,仍可依 不同要求,來達成實施之均等之效果。 The following provides an illustrative description for the implementation of this creation, but this is not the only form of implementation of this creation. The method steps and synthesis sequence of the embodiments in the creation can still be based on Different requirements to achieve equal effect of implementation.
參閱圖1之敘述,結合下方詳細敘述補充及具體實施例進行描述。本創作揭示之含活性成分酵母之微粒結構,包含核心體12與包覆體11兩部分,包覆體11包覆於核心體12外層用於保護核心體之成分。重量分布,核心體12約為60-90%,最佳為70-80%。包覆體11約佔10-40%,最佳為20-30%。
Referring to the description of FIG. 1 , the following detailed description supplements and specific embodiments will be described. The microparticle structure containing the active ingredient yeast disclosed in the present invention includes two parts, a
於本創作較佳之實施例,核心體12應包含益生元23,用以提供酵母22於微粒內穩定之環境,構築核心體之基本架構,並且釋放至體內提供腸道益生菌穩正向之助益,所述之益生元23包含但不限於木寡醣、菊醣、乳糖、半乳糖、寡醣、果寡醣等。核心體12所包含之益生元23應占總重之20-40%。
In the preferred embodiment of this creation, the
於本創作較佳之實施例,酵母22與有效成分21應與益生元23充分混合,以構成核心體12,酵母22最優選為啤酒酵母;活性成分21包含但不限於茶胺酸、Q10、兒茶素、白蘆藜醇、維生素B群、維生素C、草本萃取物、神經醯胺、鞘胺醇等。酵母22與活性成分21占總重應為20-50%。
In the preferred embodiment of this creation, the
於本創作較佳之實施例,核心體12應視情況混合防潮劑、抗氧化劑、吸濕劑、螯合劑、膨潤劑、黏合劑,最終核心體12經噴霧、造粒、乾燥後應為球狀供後續包覆。
In the preferred embodiment of this creation, the
本創作較佳之實施例,包覆體11應包裹於核心體外側,用以隔絕核心體12及外在環境,保護核心體12之成分不受外圍因素之影響。包覆體11可構成穩定之粒狀結構,可在造粒時保持粒狀並且於胃中保護核心體12之成分。所使用之包覆成分包括但不限於葡聚醣、澱粉、纖維素、環
糊精等。
In a preferred embodiment of the present invention, the
包覆體11添加於粒狀之核心體12混合,兩方混合應超過30分鐘確保完全包覆與均勻。30分鐘後應執行乾式造粒,並適當調整黏合劑及潤滑劑以防止沾黏或崩散。
The
由上述揭示內容之實施方式揭示本創作之含活性成分酵母之微粒結構,藉由結構中的外層包覆體11保護核心體12的成分,不僅可作為長期保存的劑型,且可免於核心體12的有效成分在生物體的消化道中過早受到降解失活,並可根據核心體12的成分的特性及欲到達目標釋放區域,調控外層結構之包覆體11及添加劑以達目的。
According to the embodiments of the above disclosure, the microparticle structure of yeast containing the active ingredient of the present creation is disclosed, and the components of the
11:包覆體 11: Covering body
12:核心體 12: Core Body
21:活性成分 21: Active Ingredients
22:酵母 22: Yeast
23:益生元 23: Prebiotics
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110209436U TWM624636U (en) | 2021-08-09 | 2021-08-09 | Structure of micro-complex with ingredients and yeast |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110209436U TWM624636U (en) | 2021-08-09 | 2021-08-09 | Structure of micro-complex with ingredients and yeast |
Publications (1)
Publication Number | Publication Date |
---|---|
TWM624636U true TWM624636U (en) | 2022-03-21 |
Family
ID=81747857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110209436U TWM624636U (en) | 2021-08-09 | 2021-08-09 | Structure of micro-complex with ingredients and yeast |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWM624636U (en) |
-
2021
- 2021-08-09 TW TW110209436U patent/TWM624636U/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016511271A (en) | Oral nutrition and pharmaceutical composition for veterinary medicine | |
KR102557219B1 (en) | bacterial composition | |
EP1928426B1 (en) | Method for stabilising pharmaceutical administration forms that contain micro-organisms | |
JP6948339B2 (en) | Stable dry composition containing no or few sugars | |
CA2700983C (en) | Composition and method of stabilized sensitive ingredient | |
US11602503B2 (en) | Delivery system | |
CN102946872A (en) | Micropellet compositions comprising pancreatin containing digestive enzyme mixtures | |
EP3646858A1 (en) | Encapsulated formulations | |
CN104027311A (en) | Dimethyl fumarate-containing enteric slow-release pellet | |
US20120093939A1 (en) | Oral formulations | |
CN108434119B (en) | Preparation method of protein oral micro-capsule preparation | |
TWM624636U (en) | Structure of micro-complex with ingredients and yeast | |
CN105534950A (en) | Production method for kitasamycin solid micro-capsules for feed | |
US20220193033A1 (en) | New delivery system for specific water-soluble vitamins | |
JP2011251959A (en) | Ambroxol-containing preparation particle | |
US20120003303A1 (en) | Oral enteric antidepressant formulation | |
US20060292216A1 (en) | Enteric delivery of (-)-hydroxycitric acid | |
CN104225596A (en) | Pharmaceutical composition for treating gastritis and gastric ulcers | |
CN101897674B (en) | L-cysteine tablet and preparation method thereof | |
Kane-Dumbre et al. | DRUG DELIVERY STRATEGIES FOR HELICOBACTER PYLORI INFECTION MANAGEMENT: AN OVERVIEW. | |
US10213453B2 (en) | Control release of fat soluble antioxidants from an oral formulation and method | |
US20220226254A1 (en) | New delivery system for fat soluble vitamins | |
Sichkar | EFFECT OF EXCIPIENTS ON THE QUALITY OF PELLETS AND MULTIPARTICULATE TABLETS | |
CN107625736A (en) | A kind of esomeprazole enteric capsules piece and preparation method thereof | |
WO2017078557A1 (en) | Preparing a tablet with a mechanism for enhancing the therapeutic effectiveness of a drug using a nano-dose of an analogue |